What an experience! Osgoode's team is back from their weekend of competition at the Harold G. Fox Intellectual Property Moot, and boy did we get a 'bargain'!
Last August, China's State Intellectual Property Office (SIPO) invalidated the core patent for Gilead Sciences' flagship drug Viread (as was reported by IPR Daily and a number of other news sources). This landmark ruling comes on the heels of recent changes to China's compulsory licensing scheme for pharmaceutical products. This quick-step of legislative reform followed by the […]